期刊文献+

Resectable left lower lobe non-small cell lung cancer with lymph node metastasis is related to unfavorable outcomes 被引量:3

Resectable left lower lobe non-small cell lung cancer with lymph node metastasis is related to unfavorable outcomes
下载PDF
导出
摘要 Background:Despite numerous previous studies,the consideration of tumor location as a prognostic factor in resectable non-small cell lung cancer(NSCLC)remains controversial.The present study analyzed the association between tumor location and clinical outcome in patients with resectable NSCLC who had undergone lobectomy with systematic lymphadenectomy and who had presented with varying nodal statuses.Methods:The data from a cohort of 627 eligible patients treated in Sun Yat-sen University Cancer Center between January 2000 and December 2008 were retrospectively collected,and the nodal statuses of patients with different tumor locations were compared.Cox proportional hazards regression model was used to determine the independent factors related to cancer-specific survival(CSS).Results:Multivariate analysis demonstrated that left lower lobe(LLL)tumors[hazard ratio(HR):1.465,95%confidence interval(CI)1.090-1.969,P=0.011],lymph node metastasis(HR:2.742,95%CI 2.145-3.507,P<0.001),and a tumor size of>4 cm(HR:1.474,95%CI 1.151-1.888,P=0.002)were three independent prognosticators in patients with resectable NSCLC.However,LLL tumors were associated only with CSS in node-positive patients(HR:1.528,95%CI 1.015-2.301,P=0.042),and a tumor size of>4 cm was the only independent risk predictor in the node-negative subgroup(HR:1.889,95%CI 1.324-2.696,P<0.001).Conclusions:Tumor location is related to the long-term CSS of NSCLC patients with lymph node metastasis.LLL tumors may be upstaged in node-positive patients to facilitate an optimal treatment strategy. Background:Despite numerous previous studies,the consideration of tumor location as a prognostic factor in resectable non-small cell lung cancer(NSCLC) remains controversial.The present study analyzed the association between tumor location and clinical outcome in patients with resectable NSCLC who had undergone lobectomy with systematic lymphadenectomy and who had presented with varying nodal statuses.Methods:The data from a cohort of 627 eligible patients treated in SunYat-sen University Cancer Center between January 2000 and December 2008 were retrospectively collected,and the nodal statuses of patients with different tumor locations were compared.Cox proportional hazards regression model was used to determine the independent factors related to cancer-specific survival(CSS).Results:Multivariate analysis demonstrated that left lower lobe(LLL) tumors[hazard ratio(HR):1.465,95%confidence interval(CI) 1.090-1.969,P = 0.011],lymph node metastasis(HR:2.742,95%CI 2.145-3,507,P < 0.001),and a tumor size of >4 cm(HR:1.474,95%CI 1.151-1.888,P = 0.002) were three independent prognosticators in patients with resectable NSCLC.However,LLL tumors were associated only with CSS in node-positive patients(HR:1.528,95%CI 1.015-2.301,P = 0.042),and a tumor size of >4 cm was the only independent risk predictor in the node-negative subgroup(HR:1.889,95%CI 1.324-2.696,P < 0.001).Conclusions:Tumor location is related to the long-term CSS of NSCLC patients with lymph node metastasis.LLL tumors may be upstaged in node-positive patients to facilitate an optimal treatment strategy.
出处 《Chinese Journal of Cancer》 SCIE CAS CSCD 2016年第1期35-42,共8页
基金 funded by the Guangdong Provincial Science and Technology Project(Grant No.2013B021800070)
关键词 LUNG cancer surgery Lobectomy Tumor Outcomes LYMPH node Lung cancer surgery Lobectomy Tumor Outcomes Lymph node
  • 相关文献

参考文献2

二级参考文献115

  • 1Mayo C, Bertran-Alamillo J, Molina-Vila MA, Gimenez-Capitan A, Costa C, Rosell R. Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics. 2012;13:789-802.
  • 2Siegel R, NaBhadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
  • 3Chi A, Remick S, Tse W. EGFR inhibition in non-small cell lung cancer: current evidence and future directions. Biomark Res. 2013;1:2.
  • 4Dziadziuszko R, Jassem J. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. Ann Oncol. 2012;23:x193-6.
  • 5Heuckmann JM, Rauh D, Thomas RK Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol. 2012;30:3417-20.
  • 6Rossi A. Cetuximab and non-small-cell lung cancer: end of the story? Lancet Oncok 2013;14:1251-3.
  • 7Berger C, Madshus IH, Stang E. Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis. Exp Cell Res. 2012;318:2578-91.
  • 8Sareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol. 2007;18:vi35-41.
  • 9Passaro A, Alesini D, Pochesci A, Cortesi E. Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer. Anticancer Agents Med Chem. 2014;14:646-50.
  • 10Yang X, Yang K, Kuang K. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. Curr Oncol Rep. 2014;16:390.

共引文献122

同被引文献6

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部